Oncomine Dx Target test approved to ID patients for Retevmo

Create PDF

This is the Oncomine Dx Target test’s first approval as a CDx for a therapy targeting RET-positive thyroid cancer, Thermo Fisher says, and the second approval associated with RET-positive NSCLC.